CIBC Asset Management Inc boosted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,939 shares of the medical instruments supplier’s stock after buying an additional 2,120 shares during the period. CIBC Asset Management Inc’s holdings in Becton Dickinson and were worth $11,478,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. First Trust Advisors LP raised its holdings in Becton Dickinson and by 186.3% in the third quarter. First Trust Advisors LP now owns 70,752 shares of the medical instruments supplier’s stock worth $18,466,000 after purchasing an additional 46,037 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of Becton Dickinson and by 6.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 11,149 shares of the medical instruments supplier’s stock valued at $2,909,000 after acquiring an additional 708 shares in the last quarter. Chicago Equity Partners LLC increased its holdings in shares of Becton Dickinson and by 36.9% during the third quarter. Chicago Equity Partners LLC now owns 1,187 shares of the medical instruments supplier’s stock valued at $310,000 after acquiring an additional 320 shares in the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Becton Dickinson and by 21.2% during the third quarter. Daiwa Securities Group Inc. now owns 12,612 shares of the medical instruments supplier’s stock valued at $3,292,000 after acquiring an additional 2,210 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in shares of Becton Dickinson and by 14.5% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 25,377 shares of the medical instruments supplier’s stock valued at $6,623,000 after acquiring an additional 3,205 shares in the last quarter. 83.96% of the stock is currently owned by institutional investors.
Get Becton Dickinson and alerts:
BDX has been the subject of several analyst reports. Barclays set a $260.00 price target on Becton Dickinson and and gave the company a “hold” rating in a report on Thursday, November 8th. KeyCorp raised their price target on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Citigroup reduced their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a report on Tuesday, November 13th. UBS Group initiated coverage on Becton Dickinson and in a report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price target for the company. Finally, Deutsche Bank initiated coverage on Becton Dickinson and in a report on Thursday, December 6th. They set a “buy” rating and a $280.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $253.55.
Becton Dickinson and stock opened at $246.67 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. Becton Dickinson and Co has a one year low of $208.62 and a one year high of $265.87. The firm has a market cap of $67.17 billion, a P/E ratio of 22.40, a price-to-earnings-growth ratio of 1.76 and a beta of 1.23.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The company had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the firm posted $2.48 earnings per share. Becton Dickinson and’s revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, March 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.25%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.
In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the transaction, the chief executive officer now directly owns 227,250 shares of the company’s stock, valued at $56,903,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ribo Alberto Mas sold 4,808 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the completion of the transaction, the executive vice president now directly owns 22,476 shares in the company, valued at $5,732,054.28. The disclosure for this sale can be found here. Insiders have sold 19,271 shares of company stock worth $4,862,179 over the last ninety days. 0.12% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Becton Dickinson and Co (BDX) Position Lifted by CIBC Asset Management Inc” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at www.tickerreport.com/banking-finance/4205866/becton-dickinson-and-co-bdx-position-lifted-by-cibc-asset-management-inc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: What is a Candlestick Chart?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).